Antipyrine

Summary

Antipyrine (CHEMBL277474) is an approved small-molecule non-narcotic analgesic (ATC N02BB71); indicated across 5 conditions including asthma and otitis media.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02BB71 (+3 more)
• Indications: 5 conditions
• Clinical trials: 1
• Chemistry: 188.23 Da · C11H12N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL277474
Name	Antipyrine
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	2206
ChEBI	CHEBI:31225
ATC	N02BB71, S02DA03, N02BB51, N02BB01
Molecular formula	C11H12N2O
Molecular weight	188.23
InChIKey	VEQOALNAAJBPNY-UHFFFAOYSA-N

SMILES: CC1=CC(=O)N(N1C)C2=CC=CC=C2

IUPAC name: 1,5-dimethyl-2-phenylpyrazol-3-one

ChEBI definition: A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.

Pharmacological roles (ChEBI): non-narcotic analgesic, antipyretic, non-steroidal anti-inflammatory drug, cyclooxygenase 3 inhibitor.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: Antipyrine, Antipyrinum, Fenazona, NSC-7945, Phenazone, antipyrine, Antipyrin, Anipyrine, SID56320742, SID11112159, SID104171279, SID26753718

Patent coverage: 26,083 distinct patent families (81,797 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Nicotinate phosphoribosyltransferase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NAPRT	9	Ki	1	nM	CHEMBL_ACT_19323237

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
asthma	2	MONDO:0004979	MONDO:0004979
otitis media	2	MONDO:0005441	MONDO:0024330

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02037893	PHASE2	COMPLETED	Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).